Skip to main content
Fig. 1 | Alzheimer's Research & Therapy

Fig. 1

From: Pharmacokinetics and pharmacodynamic effect of crenezumab on plasma and cerebrospinal fluid beta-amyloid in patients with mild-to-moderate Alzheimer’s disease

Fig. 1

Schematic representation of the TMDD model structure. According to Michaelis–Menten approximation, the drug–target complex is expected to be in quasi-equilibrium with the concentration of monoclonal antibody > > target concentration. Abbreviations: AAβ amount of beta-amyloid, Aβ beta-amyloid, Ccren concentration of crenezumab, IV intravenous, Kd equilibrium constant governing antibody-ligand binding, kdeg first-order rate constant for free ligand degradation, kint zero-order input rate constant for ligand, SC subcutaneous, TMDD target-mediated drug disposition

Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193